Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP ...

Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

The new multiyear agreement will allow the Danish pharma to use Gefion’s computational power to “process vast datasets” with ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

Healthcare & Pharmaceuticalscategory· June 10, 2025 Novo Nordisk starts new CagriSema weightloss drug trial Novo Nordisk has launched a new late-stage trial for its experimental next-generation ...